MetaCap

Crescent Biopharma Inc. (CBIO)

NASDAQ: CBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

13.00+0.09 (+0.70%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CBIO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$543.21M
EPS (TTM)
-$7.29
Ex-dividend date
Jan 13, 2023
52-week range
8.72 – 27.41
Day range
12.53 – 13.30
Volume / Avg
422.37K / 361.17K
Beta
—

52-week range

$8.72$27.41

CBIO stock today

Shares of Crescent Biopharma (CBIO) finished higher on Nov 20 at $13.00, a gain of 0.70% or $0.09 per share, versus the S&P 500's 3.70% decline. Shares are 52.6% below their 52-week high of $27.41, set on Apr 22, 2026 and 49.1% above the 52-week low of $8.72, in the middle of the past year's range. CBIO is up 9.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 0.5%.

Crescent Biopharma has posted a net loss over the last twelve months (EPS of -$7.29), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Crescent Biopharma

Company profile

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Joshua T. Brumm
Headquarters
Waltham, MA
Employees
80
IPO year
2014

Financial highlights

Full financials

In fiscal 2025, Crescent Biopharma generated $10.8 million in revenue. Crescent Biopharma reported a net loss of $153.9 million, compared with a loss of $37.9 million a year earlier. Operating margin was -1407.5%.

Crescent Biopharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$10.84M—$10.00K$75.00K$1.16M
Growth——-86.67%-93.53%-88.59%
Net income$-153.94M$-37.88M$-36.90M$-46.69M$-63.43M
EPS (diluted)—$-0.59$-0.58$-0.89$-1.23

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$32.33+148.69%

  • Strong buy 1
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $28.00High $40.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-1.27 vs $-0.72
Surprise
-76.39%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$24.00
Ex-dividend date
Jan 13, 2023

CBIO news

All CBIO news

Crescent Biopharma peers

Health Care sector
CBIO peer companies
CompanyPrice% ChgMarket capCompare
AVBPArriVent BioPharma Inc.10.52-6.57%$544.13Mvs CBIO
ACRSAclaris Therapeutics Inc.3.44-1.71%$545.63Mvs CBIO
CLYMClimb Bio Inc.9.19-0.97%$539.80Mvs CBIO
ANLAdlai Nortye Group Ltd. ADR8.55-5.63%$550.60Mvs CBIO
BCAXBicara Therapeutics Inc.8.44-7.46%$560.31Mvs CBIO
GERNGeron Corporation0.8707-4.63%$560.94Mvs CBIO
ZVRAZevra Therapeutics Inc.8.76-3.42%$521.26Mvs CBIO
ALMSAlumis Inc.3.96-8.54%$514.09Mvs CBIO

Indexes, lists and sector

Crescent Biopharma stock FAQ

What is Crescent Biopharma's stock price today?

CBIO last traded at $13.00 as of Nov 20, 4:00 PM EST, up 0.70% on the day. Prices are delayed at least 15 minutes.

Does Crescent Biopharma pay a dividend?

Yes. Crescent Biopharma pays $0.00 per share annually. The most recent dividend of $24.00 had an ex-dividend date of Jan 13, 2023.

Who is Crescent Biopharma's CEO?

Mr. Joshua T. Brumm is the chief executive officer of Crescent Biopharma Inc., which has about 80 employees.

Has CBIO ever split its stock?

Yes. The most recent CBIO stock split was a 1-for-100 split on Jun 16, 2025.

What is the CBIO 52-week high?

The 52-week high for CBIO is $27.41 and the 52-week low is $8.72. The stock is currently 52.6% below its high.

Compare CBIO